Compare Bristol-Myers Squibb Co (BMY) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Church & Dwight Co., Inc. — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Church & Dwight Co., Inc. trades at $97.03 (market cap $22.61B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.1× Church & Dwight Co., Inc.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | CHD | |
|---|---|---|
Market Cap | $116.30B | $22.61B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $105.26 |
52-Week Low | $42.60 | $81.60 |
Enterprise Value | $152.24B | $24.31B |
Dividend Yield | 4.42% | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Church & Dwight (CHD) trades at $97.16, up 0.83% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with 11.81% net margins and consistent organic growth, supported by strategic acquisitions like Miss Mouth's brand. Analyst consensus remains positive with a $105.60 price target, though cash flow trends show recent negative net flows.
CHD presents a balanced opportunity with solid brand execution and margin expansion potential, offset by cash flow volatility and competitive pressures. The stock's premium valuation requires sustained earnings growth to justify upside, with Q2 2026 earnings on July 31 as a key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
